Adagene Inc. - ADS, each representing 1.25 ordinary shares (NQ:ADAG)

4.000 +0.390 (+10.80%)

Streaming Delayed Price Updated: 12:46 PM EDT, Mar 25, 2026 Add to My Watchlist

Price and Volume

Volume	68,930
Open	3.670
Bid (Size)	3.780 (100)
Ask (Size)	4.020 (200)
Prev. Close	3.610
Today's Range	3.670 - 4.070
52wk Range	1.300 - 4.579
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA

March 17, 2026

From Adagene Inc.

Via GlobeNewswire

Top movers in Wednesday's session ↗

March 11, 2026

Via Chartmill

Performance

YTD	+117.4%	+117.4%
1 Month	+24.2%	+24.2%
3 Month	+116.2%	+116.2%
6 Month	+95.1%	+95.1%
1 Year	+126.0%	+126.0%

More News

Adagene to Participate in Two Upcoming Investor Conferences

February 17, 2026

From Adagene Inc.

Via GlobeNewswire

Adagene Provides Business Update and 2026 Objectives

January 23, 2026

From Adagene Inc.

Via GlobeNewswire

Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic ↗

July 15, 2025

Via Stocktwits

These stocks are gapping in today's session ↗

December 16, 2025

Via Chartmill

Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)

December 16, 2025

From Adagene Inc.

Via GlobeNewswire

Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

November 13, 2025

From Adagene Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 11, 2025

Via Benzinga

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

October 31, 2025

From Adagene Inc.

Via GlobeNewswire

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

September 16, 2025

From Adagene Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 09, 2025

Via Benzinga

Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China

September 05, 2025

From Adagene Inc.

Via GlobeNewswire

Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

September 03, 2025

From Adagene Inc.

Via GlobeNewswire

Adagene to Participate in Two Investor Conferences in September

August 26, 2025

From Adagene Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

August 14, 2025

Via Benzinga

Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates

August 12, 2025

From Adagene Inc.

Via GlobeNewswire

This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

August 06, 2025

Via Benzinga

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

July 15, 2025

From Adagene Inc.

Via GlobeNewswire

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

July 08, 2025

From Adagene Inc.

Via GlobeNewswire

Adagene announces up to $25 million strategic investment from Sanofi

July 01, 2025

From Adagene Inc.

Via GlobeNewswire

Adagene to Present at Jefferies Global Healthcare Conference 2025

May 27, 2025

From Adagene Inc.

Via GlobeNewswire

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025

From Adagene Inc.

Via GlobeNewswire

Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

April 28, 2025

From Adagene Inc.

Via GlobeNewswire

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

April 23, 2025

From Adagene Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Adagene Inc. - ADS, each representing 1.25 ordinary shares publicly traded?

Yes, Adagene Inc. - ADS, each representing 1.25 ordinary shares is publicly traded.

What exchange does Adagene Inc. - ADS, each representing 1.25 ordinary shares trade on?

Adagene Inc. - ADS, each representing 1.25 ordinary shares trades on the Nasdaq Stock Market

What is the ticker symbol for Adagene Inc. - ADS, each representing 1.25 ordinary shares?

The ticker symbol for Adagene Inc. - ADS, each representing 1.25 ordinary shares is ADAG on the Nasdaq Stock Market

What is the current price of Adagene Inc. - ADS, each representing 1.25 ordinary shares?

The current price of Adagene Inc. - ADS, each representing 1.25 ordinary shares is 4.000

When was Adagene Inc. - ADS, each representing 1.25 ordinary shares last traded?

The last trade of Adagene Inc. - ADS, each representing 1.25 ordinary shares was at 03/25/26 12:46 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.